RORγt/DHODH-IN-3 (compound (S)-14d) is a potent, orally active dual inhibitor of RORγt (IC50: 0.098 μM) and DHODH (IC50: 0.432 μM).RORγt/DHODH-IN-1 has significant in vivo anti-inflammatory effects.

DHODH-IN-3 is an effective inhibitor of human dihydroorotate dehydrogenase (HsDHODH) with IC50 value of 261 nM. DHODH-IN-3 binds to the ubiquinone binding cavity in DHODH with a Kiapp of 32 nM. DHODH-IN-3 has the potential to treat malaria.

hDHODH-IN-3 is an inhibitor of human dihydroorotate dehydrogenase with a pMIC50 value of 8.6. hDHODH-IN-3 can inhibit measles virus replication.

UCK2 Inhibitor-3 is a non-competitive inhibitor targeting uridine-cytidine kinase 2 (UCK2), a key enzyme in the pyrimidine salvage pathway, with an IC50 value of 16.6 μM. Notably, UCK2 can partially substitute for dihydroorotate dehydrogenase (DHODH) in infected or rapidly dividing cells, facilitating effective uridine salvage. Furthermore, UCK2 Inhibitor-3 exhibits inhibition of DNA polymerase eta and kappa, with IC50 values of 56 μM and 16 μM, respectively.